It can also estimate chances of cancer recurrence
The test also helps to estimate how likely the chances are that the breast cancer will return after treatment, allowing patients to either raise their guard or lower it, depending on the results. The result is less uncertainty in the future, allowing for the patients to suffer through less stress.
Oncotype DX only tests for mutations caused by the breast cancer. It does not look at hereditary genetics, such as the BRCA1 and BRCA2 genes. Those factors are still important and should be looked at as well.